[go: up one dir, main page]

IN2014MN02554A - - Google Patents

Info

Publication number
IN2014MN02554A
IN2014MN02554A IN2554MUN2014A IN2014MN02554A IN 2014MN02554 A IN2014MN02554 A IN 2014MN02554A IN 2554MUN2014 A IN2554MUN2014 A IN 2554MUN2014A IN 2014MN02554 A IN2014MN02554 A IN 2014MN02554A
Authority
IN
India
Prior art keywords
inhibitors
relates
protein kinase
present
tec
Prior art date
Application number
Inventor
Alain Laurent
Yannick Rose
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of IN2014MN02554A publication Critical patent/IN2014MN02554A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular the present invention relates to inhibitors of the members of the Tec Src and Btk protein kinase families.
IN2554MUN2014 2012-07-06 2013-07-03 IN2014MN02554A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA2782774A CA2782774A1 (en) 2012-07-06 2012-07-06 Protein kinase inhibitors
PCT/CA2013/000612 WO2014005217A1 (en) 2012-07-06 2013-07-03 Protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2014MN02554A true IN2014MN02554A (en) 2015-07-24

Family

ID=49881186

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2554MUN2014 IN2014MN02554A (en) 2012-07-06 2013-07-03

Country Status (12)

Country Link
US (2) US9447102B2 (en)
EP (1) EP2870158B1 (en)
JP (1) JP6190881B2 (en)
KR (2) KR20180107328A (en)
CN (1) CN104718207B (en)
BR (1) BR112014033056A2 (en)
CA (2) CA2782774A1 (en)
ES (1) ES2631228T3 (en)
HK (1) HK1209726A1 (en)
IN (1) IN2014MN02554A (en)
RU (1) RU2679122C2 (en)
WO (1) WO2014005217A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2782774A1 (en) * 2012-07-06 2014-01-06 Pharmascience Inc. Protein kinase inhibitors
CA2833701A1 (en) * 2013-11-19 2015-05-19 Pharmascience Inc. Protein kinase inhibitors
CA2833867A1 (en) 2013-11-21 2015-05-21 Pharmascience Inc. Protein kinase inhibitors
CA2834528A1 (en) * 2013-11-26 2015-05-26 Pharmascience Inc. Protein kinase inhibitors
CN103787839B (en) * 2014-01-21 2015-12-02 苏州昊帆生物科技有限公司 The method of synthesis 2,3,4,5,6-Pentafluorophenol
EP3337805A4 (en) * 2015-05-27 2019-04-03 Pharmascience Inc. Inhibitors of the tec kinase enzyme family
JP7337502B2 (en) * 2015-09-16 2023-09-04 ロクソ オンコロジー， インコーポレイテッド Pyrazolopyrimidine derivatives as BTK inhibitors for the treatment of cancer
WO2017134685A2 (en) * 2016-02-02 2017-08-10 Sun Pharma Advanced Research Company Limited Novel hydrazino compounds as btk inhibitors
JP6737952B2 (en) * 2016-08-17 2020-08-12 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Ｓｈｅｎｚｈｅｎ ＴａｒｇｅｔＲｘ，Ｉｎｃ． Fused bicyclic compounds for inhibiting tyrosine kinase activity
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2023500906A (en) 2019-11-08 2023-01-11 インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） Methods of treating cancers with acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2023002691A (en) * 2020-09-03 2023-05-03 Amgen Inc DESYMETRIZATION OF DIOL THROUGH NUCLEOPHILIC AROMATIC SUBSTITUTION.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3736728A1 (en) * 1987-10-29 1989-05-11 Siemens Ag PRINTER INK
EP0589335B1 (en) * 1992-09-24 2003-06-18 Hoechst Aktiengesellschaft N1-Substituted- (1H)-1,2,3-Triazolo (4,5-d) pyrimidines, process for their preparation and their use as antiviral means
WO2001019828A2 (en) * 1999-09-17 2001-03-22 Basf Aktiengesellschaft Kinase inhibitors as therapeutic agents
DE10031584A1 (en) * 2000-06-29 2002-01-10 Merck Patent Gmbh 5-aminoalkyl-pyrazolo [4,3-d] pyrimidine
US20030199525A1 (en) * 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
KR101425248B1 (en) * 2007-03-28 2014-08-06 파마시클릭스, 인코포레이티드 Inhibitor of bruton tyrosine kinase
CA2782774A1 (en) * 2012-07-06 2014-01-06 Pharmascience Inc. Protein kinase inhibitors
EP2914296B2 (en) * 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators

Also Published As

Publication number Publication date
KR101903123B1 (en) 2018-10-01
US20160375027A1 (en) 2016-12-29
RU2679122C2 (en) 2019-02-06
RU2014151421A (en) 2016-08-27
CN104718207A (en) 2015-06-17
HK1209726A1 (en) 2016-04-08
EP2870158A4 (en) 2015-12-09
WO2014005217A1 (en) 2014-01-09
EP2870158A1 (en) 2015-05-13
KR20180107328A (en) 2018-10-01
CA2782774A1 (en) 2014-01-06
JP2015521987A (en) 2015-08-03
CA2878332C (en) 2019-04-30
US9795608B2 (en) 2017-10-24
BR112014033056A2 (en) 2017-06-27
US20150344478A1 (en) 2015-12-03
US9447102B2 (en) 2016-09-20
JP6190881B2 (en) 2017-08-30
ES2631228T3 (en) 2017-08-29
KR20150041784A (en) 2015-04-17
CA2878332A1 (en) 2014-01-09
CN104718207B (en) 2017-08-15
EP2870158B1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
IN2014MN02554A (en)
EA201400833A1 (en) NEW INDOLESINE COMPOUNDS, METHOD OF THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
TN2014000138A1 (en) Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases.
UA116648C2 (en) FUMARATS AS A PRODUCT AND THEIR USE IN THE TREATMENT OF DIFFERENT DISEASES
PH12014000179A1 (en) New pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them
MX378194B (en) Organic compounds
PH12015501385A1 (en) Autotaxin inhibitors
TN2014000516A1 (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
MX357305B (en) Compounds and compositions for inhibiting the activity of abl1, abl2 and bcr-abl1.
PH12016500094A1 (en) Autotaxin inhibitors
PH12016500057A1 (en) Novel indolizine compounds, a process for their preparation and pharmaceutical compositions containing them
GEP20247677B (en) Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
MX353806B (en) Quinolines as fgfr kinase modulators.
IN2014CN00568A (en)
PH12013501922A1 (en) Protein kinase inhibitors
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
EA201590161A1 (en) COMPOSITIONS OF ETHANRECEPT DIFFERENTLY DIFFERENT BY REDUCTION OF PARTICLES OF A REVERSIBLE RANGE
TN2013000400A1 (en) Imidazopyridazines as akt kinase inhibitors
MY166449A (en) Pharmaceutical composition of rosuvastatin calcium
GEP20207108B (en) Substituted 2,4 diamino-quinoline as new anticancer agents
IN2014MN02338A (en)
MX364479B (en) Novel derivatives of indole and pyrrole, method for the production thereof and pharmaceutical compositions containing same.
PH12015501175A1 (en) Substituted pyridopyrazines as syk inhibitors
MX2013013436A (en) Substituted indole derivatives for the treatment of immunological disorders.
IN2015DN00950A (en)